Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
1.
Asian j. androl ; Asian j. androl;(6): 847-853, 2008.
Article in English | WPRIM | ID: wpr-284735

ABSTRACT

<p><b>AIM</b>To evaluate whether the response to sildenafil administration in patients with arterial erectile dysfunction (ED) was related to their peak systolic velocity (PSV), peripheral atherosclerosis, cardiovascular risk factors (RF) and/or comorbidities at low cardiovascular risk.</p><p><b>METHODS</b>We enrolled 97 patients with 1-2 RF and comorbidities, combined with arterial ED alone (group A, n = 27), ED plus atherosclerotic carotid artery (group B, n = 23), ED plus lower limb artery abnormalities (group C, n = 25), and ED plus carotid and lower limb artery abnormalities (group D, n = 22). Sildenafil efficacy (100 mg twice a week for 12 weeks) was also examined in patients with =or>3 RF, peripheral atherosclerosis and no cardiovascular comorbidities (group E, n = 20).</p><p><b>RESULTS</b>Median PSV was 24.1, 21.0, 19.3, 14.5 and 17.5 cm/s in groups A, B, C, D and E, respectively. Sildenafil response was higher in group A patients (77.8%), intermediate in groups B and C (65.2% and 56%) and lowest in groups D (45.4%) and E (50%), and the response in latter two groups was significantly lower than in the other three groups. In addition, sildenafil response was negatively influenced by: =or>3 RF, peripheral atherosclerosis and no systemic comorbidity, or presence of 1-2 RF associated with extended atherosclerosis and comorbidities. The number of comorbidities was positively related to atherosclerosis localization or extension (25, 35, 38 and 47 in groups A, B, C and D, respectively).</p><p><b>CONCLUSION</b>Low sildenafil efficacy in patients with arterial ED was associated with extended atherosclerosis. These patients should undergo extensive ultrasonography and a full cardiovascular examination.</p>


Subject(s)
Aged , Humans , Male , Middle Aged , Arterial Occlusive Diseases , Drug Therapy , Atherosclerosis , Cardiovascular Diseases , Drug Therapy , Erectile Dysfunction , Drug Therapy , Lower Extremity , Physical Examination , Piperazines , Therapeutic Uses , Purines , Therapeutic Uses , Regional Blood Flow , Physiology , Retrospective Studies , Risk Factors , Sildenafil Citrate , Sulfones , Therapeutic Uses , Treatment Outcome , Vasodilator Agents , Therapeutic Uses
SELECTION OF CITATIONS
SEARCH DETAIL